MX2013013228A - Particulas similares a virus y proceso para prepararlas. - Google Patents

Particulas similares a virus y proceso para prepararlas.

Info

Publication number
MX2013013228A
MX2013013228A MX2013013228A MX2013013228A MX2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A MX 2013013228 A MX2013013228 A MX 2013013228A
Authority
MX
Mexico
Prior art keywords
vlps
particles
virus
preparing same
ssrna
Prior art date
Application number
MX2013013228A
Other languages
English (en)
Inventor
Denis Leclerc
Pierre Savard
Original Assignee
Folia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Folia Biotech Inc filed Critical Folia Biotech Inc
Publication of MX2013013228A publication Critical patent/MX2013013228A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/26042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona un proceso in vitro para preparar partículas similares a virus (VLPs) a partir de la proteína de recubrimiento de virus de mosaico de papaya recombinante y ssRNA, que permite la producción a gran escala de VLPs en alto rendimiento. También se proporcionan VLPs que comprenden ssRNA preparadas mediante el proceso in vitro. Las VLPs se pueden utilizar como adyuvantes y cuando se fusionan a un antígeno, como vacunas. También se proporciona el uso de las VLPs para la estimulación de la respuesta inmune innata.
MX2013013228A 2011-05-13 2012-05-01 Particulas similares a virus y proceso para prepararlas. MX2013013228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485955P 2011-05-13 2011-05-13
PCT/CA2012/050279 WO2012155262A1 (en) 2011-05-13 2012-05-01 Virus-like particles and process for preparing same

Publications (1)

Publication Number Publication Date
MX2013013228A true MX2013013228A (es) 2013-12-12

Family

ID=47176093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013228A MX2013013228A (es) 2011-05-13 2012-05-01 Particulas similares a virus y proceso para prepararlas.

Country Status (11)

Country Link
US (2) US20140154288A1 (es)
EP (2) EP2707027A4 (es)
JP (2) JP6093926B2 (es)
CN (2) CN103687942A (es)
AU (1) AU2012255595A1 (es)
BR (2) BR112013029144A2 (es)
CA (2) CA2835967A1 (es)
DK (1) DK2707480T3 (es)
MX (1) MX2013013228A (es)
NO (1) NO2800866T3 (es)
WO (2) WO2012155262A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6093926B2 (ja) 2011-05-13 2017-03-15 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルス組成物および自然免疫応答刺激のためのその使用
CA2924819A1 (en) * 2013-09-19 2015-03-26 Folia Biotech Inc. Papaya mosaic virus and virus-like particles in cancer therapy
WO2015153883A1 (en) 2014-04-02 2015-10-08 Case Western Reserve University Vaccination using plant virus particles linked to her2 antigens
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
CA2958222A1 (en) * 2014-09-11 2016-03-17 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
WO2016127262A1 (en) * 2015-02-12 2016-08-18 Folia Biotech Inc. Multimerized orthomyxovirus nucleoprotein and uses thereof
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
MX2017008627A (es) * 2017-06-28 2019-02-08 Univ Mexico Nac Autonoma Vlps derivadas de virus de planta con dsrna encapsidado y metodo de sintesis.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
PT1523329E (pt) 2002-07-05 2013-10-08 Folia Biotech Inc Partícula viral adjuvante
CN100404070C (zh) * 2003-07-10 2008-07-23 赛托斯生物技术公司 包装的病毒样颗粒
JP4966661B2 (ja) 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
JP2010508860A (ja) * 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
WO2008058369A1 (en) 2006-11-15 2008-05-22 Folia Biotech Inc. Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof
US7799281B2 (en) 2007-01-16 2010-09-21 Festo Corporation Flux concentrator for biomagnetic particle transfer device
US20100316665A1 (en) 2007-01-26 2010-12-16 Denis Leclerc Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
CA2742288A1 (en) 2008-07-30 2010-02-04 Folia Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
US20110105383A1 (en) 2008-09-10 2011-05-05 Magnus Hook Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
JP6093926B2 (ja) 2011-05-13 2017-03-15 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルス組成物および自然免疫応答刺激のためのその使用

Also Published As

Publication number Publication date
EP2707480A4 (en) 2015-01-07
AU2012255595A1 (en) 2013-12-12
JP2014519817A (ja) 2014-08-21
EP2707480A1 (en) 2014-03-19
BR112013029143A2 (pt) 2017-07-11
US9833504B2 (en) 2017-12-05
DK2707480T3 (da) 2017-11-13
BR112013029144A2 (pt) 2017-07-11
CA2835967A1 (en) 2012-11-22
EP2707480B1 (en) 2017-08-02
NO2800866T3 (es) 2018-04-14
JP2014514350A (ja) 2014-06-19
CA2835972A1 (en) 2012-11-22
JP6093926B2 (ja) 2017-03-15
US20140154288A1 (en) 2014-06-05
CN103648528A (zh) 2014-03-19
US20140255439A1 (en) 2014-09-11
CN103687942A (zh) 2014-03-26
WO2012155262A1 (en) 2012-11-22
EP2707027A1 (en) 2014-03-19
EP2707027A4 (en) 2015-06-03
JP6213461B2 (ja) 2017-10-18
WO2012155261A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
IL236650B (en) Immunogenic combination, nucleic acids or vectors encoding it, host cells or compositions comprising them, and therapeutic uses thereof, process of producing an infectious virus and method for recombinant production of the mycobacterial antigens
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
JP2013216685A5 (es)
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MY187462A (en) Modified virus-like particles of cmv
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
MX350274B (es) Vacunas para hsv-2.
MX2014007516A (es) Procesos que utilizan vlps con capsides resistentes a hidrolasas.
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
IN2015DN02546A (es)
IN2014DN05695A (es)
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
IN2014DN05805A (es)
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
MX2014000753A (es) Procedimiento para producir antigeno viral y vacunas.
MX355501B (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
MX2019005298A (es) Composiciones y metodos que usan capsides resistentes a hidrolasas.
JP2014519817A5 (es)
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza

Legal Events

Date Code Title Description
FA Abandonment or withdrawal